Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
47°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
60.28
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
January 08, 2025
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.
Via
Benzinga
Topics
ETFs
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
January 08, 2025
Via
Benzinga
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
January 04, 2025
Via
The Motley Fool
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City
January 03, 2025
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape.
Via
Benzinga
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
December 31, 2024
Via
Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
December 31, 2024
Via
Benzinga
2 High-Yield Dividend Stocks to Buy Early in 2025
December 31, 2024
Via
The Motley Fool
Bristol Myers Squibb Stock Earns 83 RS Rating
December 19, 2024
On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
Via
Investor's Business Daily
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
January 03, 2025
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
December 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential.
December 27, 2024
Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout.
Via
Chartmill
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
December 23, 2024
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:
Via
Benzinga
Topics
ETFs
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
December 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
December 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
December 23, 2024
Via
The Motley Fool
Topics
ETFs
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21
December 21, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 16-20, 2024.
Via
Talk Markets
Topics
Stocks / Equities
Want Decades of Passive Income? 3 Stocks to Buy Right Now
December 21, 2024
Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.
Via
The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
December 19, 2024
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Via
Benzinga
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
December 19, 2024
Via
The Motley Fool
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
December 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
December 19, 2024
Via
The Motley Fool
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
December 19, 2024
Via
The Motley Fool
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
December 18, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
December 18, 2024
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.
Via
Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
December 18, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
December 17, 2024
HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties and pricing agreement termination.
Via
Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
December 17, 2024
Via
Benzinga
Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook
December 16, 2024
Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to...
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
December 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.